Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma

Phase 4

Completed

Conditions: Multiple Myeloma

Interventions: Procedure: Autologous peripheral blood stem cell transplant
Drug: Lenalidomide
Procedure: Stem cell collection
Drug: Dexamethasone
Drug: Melphalan
Drug: G-CSF
Drug: Cyclophosphamide
Drug: Mesna

First Posted Date: 2012-11-22

Last Posted Date: 2020-02-05

Lead Sponsor: Columbia University

Target Recruit Count: 60

Registration Number: NCT01731886

Locations: 🇺🇸
Columbia University, New York, New York, United States

Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 2

Completed

Conditions: Plasma Cell Leukemia
Plasma Cell Myeloma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Biological: Elotuzumab
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Drug: Melphalan
Biological: Natural Killer Cell Therapy
Biological: Umbilical Cord Blood-Derived Lymphocyte Therapy

First Posted Date: 2012-11-20

Last Posted Date: 2024-06-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 72

Registration Number: NCT01729091

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Phase 1

Terminated

Conditions: Lymphoma

Interventions: Drug: Carfilzomib
Drug: Lenalidomide
Drug: Rituximab

First Posted Date: 2012-11-20

Last Posted Date: 2019-10-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT01729104

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma

Phase 2

Completed

Conditions: Adult T-Cell Leukemia-Lymphoma

Interventions: Drug: Lenalidomide

First Posted Date: 2012-11-09

Last Posted Date: 2018-05-29

Lead Sponsor: Celgene

Target Recruit Count: 26

Registration Number: NCT01724177

Locations: 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵
Kumamoto University Hospital, Kumamoto, Japan
🇯🇵
Kagoshima University Medical and Dental Hospital, Kagoshima, Japan

and more 15 locations

Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.

Phase 2

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Lenalidomide
Drug: Epoetin beta

First Posted Date: 2012-10-31

Last Posted Date: 2016-11-08

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 132

Registration Number: NCT01718379

Locations: 🇲🇨
centre hopitalier princesse Grace, Monaco, Monaco
🇫🇷
Hopital Saint Antoine, Paris, France
🇫🇷
CH de la Cote Basque, Bayonne, France

and more 45 locations

Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Completed

Conditions: Plasma Cell Myeloma
Hematopoietic Cell Transplantation Recipient

Interventions: Drug: Ixazomib Citrate
Drug: Lenalidomide
Other: Questionnaire Administration

First Posted Date: 2012-10-31

Last Posted Date: 2023-12-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 83

Registration Number: NCT01718743

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lenalidomide
Drug: Temsirolimus
Drug: Quinidine
Drug: Diphenhydramine

First Posted Date: 2012-10-24

Last Posted Date: 2019-11-08

Lead Sponsor: Celgene

Target Recruit Count: 31

Registration Number: NCT01712828

Locations: 🇺🇸
Covance Clinical Research Unit Dallas, Dallas, Texas, United States

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

Phase 1

Active, not recruiting

Conditions: Recurrent Neuroblastoma
Refractory Neuroblastoma

Interventions: Biological: Dinutuximab
Drug: Isotretinoin
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Other: Pharmacological Study

First Posted Date: 2012-10-22

Last Posted Date: 2024-11-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT01711554

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States

and more 12 locations

Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant

Phase 2

Completed

Conditions: Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: bortezomib
Drug: lenalidomide
Other: laboratory biomarker analysis
Drug: cyclophosphamide
Procedure: quality-of-life assessment
Drug: dexamethasone

First Posted Date: 2012-10-15

Last Posted Date: 2018-09-17

Lead Sponsor: Mayo Clinic

Target Recruit Count: 3

Registration Number: NCT01706666

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Baylor Medical Center, Garland, Texas, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

and more 1 locations

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)

Phase 1

Completed

Conditions: HIV-1 Infection

Interventions: Drug: Lenalidomide placebo
Drug: Lenalidomide
Drug: Vacc-4X
Drug: rhuGM-CSF

First Posted Date: 2012-10-11

Last Posted Date: 2017-03-08

Lead Sponsor: Bionor Immuno AS

Target Recruit Count: 36

Registration Number: NCT01704781

Locations: 🇩🇪
EIPMED - Gesellschaft fűr epidemiologische und klinische Forschung in der Medizin mbH Rubensstrasse 125, Berlin, Germany
🇩🇪
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
🇩🇪
Charite Campus, Virchow-Klinikum Medizinische Klinik mit Schwerpunkt Infektiologie Station 59 (Suedring 11) Augustenburger Platz 1, Berlin, Germany

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy